Key Points:
- Remix Therapeutics raised $60 million in funding to support the clinical development of its lead program, REM-422, and further advancement of its pipeline of RNA processing targeted therapeutics.
- The funding round was led by The Column Group and included participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor, as well as new investors WTT Investment and Willett Advisors.
Cambridge-based biotechnology company, Remix Therapeutics, has secured $60 million in a funding round led by The Column Group. The company will use the funds to support the clinical development of its lead program, REM-422, and further advance its pipeline of RNA processing targeted therapeutics. Existing investors, including Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor, also participated in the funding round, along with new investors WTT Investment and Willett Advisors.
Remix Therapeutics is focused on developing novel small molecule therapies that aim to reprogram RNA processing and treat diseases. The company’s REMaster technology platform enables the identification of RNA processing patterns and the targeting of key RNA processing steps to modulate gene expression. By altering the way genes are read from the genome, Remix Therapeutics’ therapeutic approach has the potential to address disease drivers at their origin.
Remix Therapeutics’ lead program, REM-422, will be the main focus of the company’s clinical development efforts. The funding will support the advancement of REM-422 as well as the development of other RNA processing targeted therapeutics in the company’s pipeline.
This funding round marks another significant milestone for Remix Therapeutics as it continues to make progress in the development of its RNA-focused therapies. With the support of The Column Group and a strong group of existing and new investors, the company is well-positioned to advance its programs and potentially bring new treatment options to patients in the future.
Overall, the funding will provide Remix Therapeutics with the financial resources necessary to continue its research and development efforts and accelerate the clinical development of its lead program and pipeline of RNA processing targeted therapeutics. With its innovative approach to RNA reprogramming, the company is poised to make a significant impact in the field of biotechnology and potentially transform the treatment landscape for a variety of diseases.
